Sign in
LPCN Stock Price, Chart, Stats & News
Lipocine Inc.
Save
Lipocine Inc. (LPCN) does not currently pay a dividend.
17.31M
Market cap
–
Current P/E
5.64x
Forward P/E
LPCN chart
Fundamentals
Gross margin | -8.86% |
Operating margin | -524.69% |
Pretax margin | -487.04% |
Net margin | -487.06% |
Effective tax rate | -0.00% |
ROA | -56.61% |
ROE | -59.29% |
D/E | – |
Interest coverage ratio | – |
LPCN valuation
P/E | – |
P/S | 19.70x |
P/B | 2.69x |
P/CF | -3.99x |
P/FCF | -3.99x |
P/OCF | -3.99x |
PEG | 0.06x |
EV multiple | -4.28x |
About
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Similar securities
Based on sector and market capitalization
Report issue